AzTrials
AzTrials

Extensive Stage Small Cell Lung CancerPhase 2NCT04699838

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

A Phase 2 study testing Cisplatin, Carboplatin and Etoposide in people with Extensive Stage Small Cell Lung Cancer, run by Muhammad Furqan at 5 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Extensive Stage Small Cell Lung Cancer
What is being tested?
Cisplatin, Carboplatin and Etoposide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
5 sitesUnited States
Study dates
20 Apr 2021to Apr 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Age >= 18 years at the time of consent.
  • ECOG Performance Status of 0-1 within 14 days prior to registration (Appendix A of Protocol).
  • Histological or cytological confirmed small cell lung carcinoma
  • Extensive stage disease
  • Patient must be considered suitable to receive a platinum-based chemotherapy as 1st line treatment for ES-SCLC. Chemotherapy must contain either Carboplatin or Cisplatin in combination with Etoposide.
Show all 28Show fewer
  • Measurable disease according to RECIST v1.1 for solid tumors within 28 days prior to registration.
  • Prior treatment must be completed within the following number of days prior to registration:
  • --Palliative radiation: for painful bony lesion must be completed prior to registration and recovered from significant bone marrow toxicity. For patients who received WBRT, 14 days washout is required prior to study therapy. Patient's must be off steroids without worsening of symptoms related to brain metastases. Patient should be on stable doses of anti-convulsant.
  • Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to registration
  • Hematological
  • Absolute Neutrophil Count (ANC) >/= 1500/mm^3
  • Platelet >/= 100,000/mm^3
  • Hemoglobin (Hgb) >/= 9 g/dL
  • Renal
  • Creatinine </= 1.5 x ULN
  • Calculated creatinine clearance >/= 50 mL/min using the Cockcroft-Gault formula if creatinine is more than 1.5 x ULN (60 mL/min if receiving Cisplatin)
  • Hepatic
  • Bilirubin </= 1.5 x upper limit of normal (ULN), </= 3 x ULN if history of Gilbert Syndrome
  • Aspartate aminotransferase (AST) </= 2.5 x ULN (if liver metastases then </= 5 x ULN)
  • Alanine aminotransferase (ALT) </= 2.5 x ULN (if liver metastases then </= 5 x ULN)
  • Female subjects of childbearing potential and non-sterilized male subjects who intend to be sexually active during the study must agree to use a highly effective method of contraception from the time of screening, throughout the total duration of the drug treatment, and for 6 months after the last dose of study drug treatment.
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
  • Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
  • Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  • As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study
  • Ability to swallow and retain oral medication
  • Must have a life expectancy of at least 12 weeks

Who cannot join

  • Prior systemic therapy for extensive stage or recurrent SCLC
  • Patients with recurrent SCLC, who received chemotherapy or definitive chest radiation in the past for limited-stage SCLC.
  • Clinically significant active infection requiring systemic therapy
  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  • Participants who have undergone major surgery within 28 days before first dose of study drug
  • Participants who are currently receiving any other investigational agents
Show all 30Show fewer
  • Active malignancy requiring therapy other than small cell lung cancer, excluding: non-melanoma skin cancer, noninvasive colonic polyps, superficial bladder tumors, cervical cancer in-situ, ductal carcinoma in situ of the breast, monoclonal B-cell lymphocytosis, or monoclonal gammopathy of undetermined significance.
  • Diagnosis of immunodeficiency or is receiving systemic steroid therapy (> 10 mg of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to study enrolment. Patient's on physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Topical, inhaled or intra-articular steroids are not considered as systemic steroids. Steroids as premedication for hypersensitivity reaction (e.g. CT scan premedication) or prior to chemotherapy is allowed.
  • Active autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
  • Patients with vitiligo or alopecia
  • Patients with hyperthyroidism or hypothyroidism (e.g., following Hashimoto syndrome) clinically stable on hormone replacement
  • Any chronic skin condition that does not require systemic immunosuppressive therapy
  • Patients with celiac disease controlled by diet alone
  • Diabetes mellitus with or without insulin replacement therapy
  • Has history of immune therapy related pneumonitis that required steroids
  • Patients with untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal carcinomatosis will be excluded. Previously treated CNS metastases and have no requirement for steroids for at least 2 weeks prior to study entry is allowed. Anticonvulsant therapy at a stable dose is permitted and must not have seizures for at least 2 weeks prior to study entry. May have residual symptoms as new baseline. Brain imaging with either MRI (preferred) or CT with contrast must be performed on all subjects at screening to evaluate brain metastases.
  • Known history of Hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  • Known history of active tuberculosis
  • History of allogeneic stem cell or solid organ transplant
  • History of Ataxia telangiectasia
  • Uncontrolled intercurrent illness including, but not limited to, serious and active uncontrolled infection, symptomatic congestive heart failure (NYHA class III-IV), active inflammatory bowel disease, unstable angina pectoris, uncontrolled seizures, or psychiatric illness/social situations that would limit compliance with study requirements
  • Participants with a known hypersensitivity to durvalumab, ceralasertib or any excipient of the product
  • Patients who have been vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
  • Refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection, with clinically significant sequelae that would preclude adequate absorption of ceralasertib.
  • Patients weighing <= 30 Kg.
  • Participants may not be receiving any medications or substances that are potent inhibitors or inducers of CYP3A4 (Appendix B of the protocol).
  • There is a required wash-out period of 5 half-lives from such agents prior to starting ceralasertib, or three weeks for St. John's Wort.
  • For non-potent inhibitors or inducers of CYP3A4, the decision to allow a patient to enroll on the study is per investigator best judgement. Note these include common azole antifungals, macrolide antibiotics, and other medications listed in the concomitant medications section. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
  • Exposure of other drugs metabolized by CYP3A4 and/or CYP2B6 may be reduced and additional monitoring may be required.
  • The use of herbal supplements or 'folk remedies' (and medications and foods that significantly modulate CYP3A activity) should be discouraged. If deemed necessary, such products may be administered with caution and the reason for use documented in the CRF.

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

United States5 sites

  • University of Maryland

    Baltimore, Maryland, 21201

  • University of Illinois Medical Center

    Chicago, Illinois, 60612

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242

Other trials in United States

About this study

Official title: A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.

Being tested
Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04699838
Study groupRoleWhat they receive
Cisplatin or Carboplatin + Etoposide + Durvalumab + CeralasertibExperimentalInitial Phase: Cycles 1-4 Cisplatin or Carboplatin: Day 1 Etoposide: Days 1-3 Durvalumab, 1500 mg: Day 1 q 3 weeks Maintenance Phase, Cycles 5+ Durvalumab, 1500 mg: Day 8 q 4 wks. Ceralasertib at 240mg po BID twice a day: Days 1-7
Receives: Drug: Cisplatin; Drug: Carboplatin; Drug: Etoposide; Drug: Durvalumab; Drug: Ceralasertib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression Free Survival (PFS)

    Progression free survival (PFS) is defined as the time from the initiation of treatment (C1D1) to the time when the criteria for disease progression is met as defined by RECIST v1.1 OR death due to any cause. The PFS is subject to right censoring due to loss to follow-up or at the end of study duration.

    Measured: From enrollment until the time of disease progression, assessed for a maximum of 24 months

Secondary outcomes (9)

  1. Time to disease progression

    Time to disease progression: Will be measured from C1D1 of treatment until the criteria for disease progression is met as defined by RECIST 1.1

    Measured: From enrollment until the time of disease progression,assessed for a maximum of 24 months

  2. Time to CNS Progression

    Time to CNS progression: Will be measured from C1D1 of treatment until the criteria for disease progression is met in the CNS (intracranial) by RECIST 1.1 criteria. Patients with CNS -only progression or those with concurrent CNS and systemic progression will be included in this analysis.

    Measured: From enrollment until the time of cns progression, assessed for a maximum of 24 months

  3. Time to Systemic Progression

    Time to Systemic progression: Will be measured from C1D1 of treatment until the criteria for systemic disease (extracranial) progression is met by RECIST 1.1. Patients with systemic-only or those with concurrent CNS and systemic progression will be included in this analysis.

    Measured: From enrollment until the time of systemic progression, assessed for a maximum of 24 months

  4. Progression free survival for maintenance therapy

    Progression free survival for maintenance therapy: Will be measured from C5D1 of first maintenance therapy until the criteria for disease progression is met as defined by RECIST 1.1

    Measured: From Cycle 5, Day 1 of maintenance therapy until disease progression, assessed for a maximum of 19 months

  5. Objective response rate (ORR)

    Objective response rate (ORR): Will include complete response (CR) + partial response (PR) and will be determined as per RECIST1.1

    Measured: 24 months

  6. Duration of Response

    Duration of Response: The period measured from the time that measurement criteria are met for complete or partial response (whichever status is recorded first) until the date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since treatment started).

    Measured: 24 months

  7. Disease Control Rate

    Disease control rate: The disease control rate is the proportion of all subjects with stable disease (SD) for 8 weeks, or partial response (PR), or complete response (CR) according to RECIST v1.1, from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment).

    Measured: 8 weeks from Cycle 1 Day 1

  8. Overall Survival (OS)

    Overall survival: Will be measured from D1 to death from any cause

    Measured: 24 months

  9. Toxicity Profile

    Describe the toxicity profile of durvalumab and ceralasertib combination therapy by the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2021
  2. Study start20 Apr 2021
  3. Primary completionJan 2027 (estimated)
  4. Study completionApr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04699838
Sponsor's protocol ID
BTCRC-LUN18-363
Status last verified
Sep 2026
First submitted
23 Dec 2020
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Cisplatin, Carboplatin and Etoposide in people with Extensive Stage Small Cell Lung Cancer, run by Muhammad Furqan at 5 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression Free Survival (PFS) (time frame: From enrollment until the time of disease progression, assessed for a maximum of 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04699838.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in